Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Clinical trial NCT05296564 · RECRUITING

Trial details

NCT number: NCT05296564
Sponsor: Hadassah Medical Organization
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sarcoma, Synovial Sarcoma,Soft Tissue Melanoma Stage IV Triple Negative Breast Cancer Metastatic Cancer Non Small Cell Lung Cancer Bladder Urothelial Carcinoma Neuroblastoma, Metastatic Ovary Cancer

Start date: 2022-04-01
Primary completion: 2027-12-30
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.